Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joshua P Cohen

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Journal of Personalized Medicine|January 8, 2015
Personalized Medicine's Bottleneck: Diagnostic Test Evidence and ReimbursementJoshua P Cohen, Abigail E Felix
Clinical Therapeutics|February 6, 2018
Challenges Involved in the Development and Delivery of Abuse-deterrent Formulations of Opioid AnalgesicsJoshua P Cohen, Mario Mendoza, Carl Roland
The American Journal of Managed Care|April 18, 2014
Complying with state and federal regulations on essential drug benefits: implementing the Affordable Care ActJoshua P Cohen, Abigail Felix, Magdalini Vasiadi
Applied Health Economics and Health Policy|November 13, 2009
Assessing comparative effectiveness research in the USJoshua P Cohen, John F P Bridges
Clinical Therapeutics|June 8, 2014
Measuring progress in neglected disease drug developmentJoshua P Cohen, Greg Sturgeon, Alisa Cohen
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 29, 2013
Management of hereditary angioedema in 2012: scientific and pharmacoeconomic perspectivesStephen A Tilles, Larry Borish, Joshua P Cohen
Nature Reviews. Drug Discovery|October 17, 2015
Market watch: Where is personalized medicine in industry heading?Christopher-Paul Milne, Joshua P Cohen, Ranjana Chakravarthy
BMJ (Clinical Research Ed.)|January 1, 2005
Switching prescription drugs to over the counterJoshua P Cohen, Cherie Paquette, Catherine P Cairns
Clinical Therapeutics|July 6, 2015
Impact of Postapproval Evidence Generation on the Biopharmaceutical IndustryChristopher-Paul Milne, Joshua P Cohen, Abigail Felix, et al.
BMJ (Clinical Research Ed.)|July 5, 2015
Restricting access to florbetapir: Medicare coverage criteria for diagnostics and drugs are inconsistentJoshua P Cohen, Jinghui Dong, Christine Y Lu, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Journal of Personalized Medicine|January 8, 2015
Personalized Medicine's Bottleneck: Diagnostic Test Evidence and ReimbursementJoshua P Cohen, Abigail E Felix
Clinical Therapeutics|February 6, 2018
Challenges Involved in the Development and Delivery of Abuse-deterrent Formulations of Opioid AnalgesicsJoshua P Cohen, Mario Mendoza, Carl Roland
The American Journal of Managed Care|April 18, 2014
Complying with state and federal regulations on essential drug benefits: implementing the Affordable Care ActJoshua P Cohen, Abigail Felix, Magdalini Vasiadi
Applied Health Economics and Health Policy|November 13, 2009
Assessing comparative effectiveness research in the USJoshua P Cohen, John F P Bridges
Clinical Therapeutics|June 8, 2014
Measuring progress in neglected disease drug developmentJoshua P Cohen, Greg Sturgeon, Alisa Cohen
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 29, 2013
Management of hereditary angioedema in 2012: scientific and pharmacoeconomic perspectivesStephen A Tilles, Larry Borish, Joshua P Cohen
Nature Reviews. Drug Discovery|October 17, 2015
Market watch: Where is personalized medicine in industry heading?Christopher-Paul Milne, Joshua P Cohen, Ranjana Chakravarthy
BMJ (Clinical Research Ed.)|January 1, 2005
Switching prescription drugs to over the counterJoshua P Cohen, Cherie Paquette, Catherine P Cairns
Clinical Therapeutics|July 6, 2015
Impact of Postapproval Evidence Generation on the Biopharmaceutical IndustryChristopher-Paul Milne, Joshua P Cohen, Abigail Felix, et al.
BMJ (Clinical Research Ed.)|July 5, 2015
Restricting access to florbetapir: Medicare coverage criteria for diagnostics and drugs are inconsistentJoshua P Cohen, Jinghui Dong, Christine Y Lu, et al.
Pageof 3